Posted by Michael Wonder on 19 Sep 2019
Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
18 September 2019 - In this study, the investigators examined the characteristics of randomised controlled trials that supported approval of cancer drugs by the EMA from 2014 to 2016.
They focused on three aspects of cancer drug trials. The first aspect was trial design. A key feature of cancer drug trials is whether they are designed to demonstrate a benefit on overall survival or quality of life.
